---
symbol: "HIMS"
name: "Hims & Hers"
date: 2026-11-06
change_pct: 9.422218406593409
direction: "up"
event_type: "contract_deal"
url: "https://perplo.app/why/HIMS/2026-11-06"
updated_at: 2026-11-06T18:07:04.345Z
---

# Why Hims & Hers (HIMS) rose 9.42% on November 6, 2026

Hims & Hers (HIMS) rose 9.42% on November 6, 2026 — Lilly GLP-1 deal lifts Hims as compounding ends.

## What happened

Hims & Hers rose 9.4% after striking a GLP-1 deal with Eli Lilly, under which it will stop compounding Zepbound. The deal moves its weight-loss offering toward branded Lilly drugs.

## Why it moved

The Lilly partnership removes the regulatory overhang tied to compounded GLP-1 drugs, which had been the main risk to Hims' growth.

## Why it matters

Within the Meme Stocks theme, Hims trades on high retail attention and sharp narrative swings. The Lilly deal gives it a fundamental catalyst that can support the rally beyond pure momentum.

## What would break the thesis

The deal's economics matter: if Lilly's terms limit Hims' margins, or if patients churn once compounded options end, the gains can reverse quickly.

## Sources

- [Hims & Hers struck a GLP-1 deal with Lilly. Its stock is rallying.](https://www.marketwatch.com/story/hims-hers-struck-a-glp-1-deal-with-lilly-its-stock-is-rallying-d06ebe60?mod=mw_rss_topstories) — MarketWatch
- [Lilly partners with Hims & Hers to offer weight-loss drugs](https://www.investing.com/news/company-news/lilly-partners-with-hims--hers-to-offer-weightloss-drugs-93CH-5007467) — Investing.com

---

Trade HIMS perpetual futures 24/7 onchain: https://perplo.app/asset/HIMS